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Although metabolomics aims at the measure-
ment of small molecules (metabolites) in a
biological sample, this knowledge requires
additional information on the related genetic
variants, epigenetic regulators and environ-
mental factors (diet, smoking, physical activi-
ty, etc.) in order to translate the knowledge
into actionable therapeutic or preventive
evidence for complex disease outcomes. We
focused on serum bilirubin, a metabolite
generated when heme oxygenase catalyzes
the degradation of heme (Figure 1). This
produces biliverdin, which is converted into
bilirubin by biliverdin reductase. Bilirubin is
further processed in hepatocytes, where
unconjugated bilirubin is conjugated by
uridine diphosphate-glucuronosyltransferase
(UDP-GT) to a water-soluble form for
excretion. For decades, increased serum
bilirubin concentrations were considered a
threatening sign of underlying liver disease
and had been associated with neonatal
jaundice. However, data from recent years
show that bilirubin is a powerful antioxidant
and suggest that slightly increased serum
bilirubin concentrations are protective against
oxidative stress-related diseases.
We analyzed subjects with metabolic syndrome
from a Mediterranean population (n=430)
recruited in the PREDIMED PLUS-Valencia trial.
Table 1 shows the main characteristics of these
participants.
Figure 1
Figure 5 shows linkage disequilibrium among
SPNs in the UGT1-cluster.
Figure 2: Human UGT1A










To examine the genetic, epigenetic and
environmental factors associated with serum
bilirubin concentrations in subjects with
metabolic syndrome from a Mediterranean
population using genomics, epigenomics and
exposomics approaches.
In subjects with Gilbert syndrome, the UDP-GT
activity is reduced to 30% of the normal,
resulting in hyperbilirubinemia. Several
polymorphisms in the UDP-GT family 1 member
A1 (UGT1A1) gene, on chromosome 2, have
been associated with the Gilbert's syndrome,
but the most common one is a TATA box
polymorphism (rs8175347). The UGT1A cluster
includes 9 similar protein-coding (Figure 2).
Figure 3: Sex-differences in serum bilirubin concentrations
in men and women
Table 2 shows GWAS results for total bilirubin in
the whole sample including both men and
women. Included in the Table are the 59 top-
ranked SNPs with P-values for association with
bilirubin concentrations at the genome-wide
level (P<5x10-8) o significance in the crude
model and/or in the model adjusted for sex and
age.
In the EWAS analysis we detected significant associations
between methylation in several CpGs in candidate genes for
bilirubin and bilirubin concentrations (i.e.: cg23938283 in
SLCO1B1; cg21620495 in UGT1A10; cg05357229 in UGT1A6;
and cg01764553 in UGT1A1). However, these CpGs were not
among the top-ranked methylated signals in the EWAS for
bilirubin concentrations. Finally, in a pilot study, we explored
the interactions between genomics, epigenomics and
environmental factors on serum bilirubin, revealing several
modulations. Our results show the multiomics contribution to
bilirubin and support the integration of metabolomics with
other omics to better understand the associations between
metabolites and health.
Figure 4: Manhattan plot
Figure 4 shows the corresponding Manhattan
plot for the GWAS analysis.
Figure 5
We found that the UGT1A gene cluster was the
locus most significantly associated with
bilirubin levels (the rs4148325-UGT1A1 SNP;
P=9.25×10-24, being the top ranked). We also
found the MROH2A at the GWAS level. Other
candidate SNPs (SLCO1B1 [solute carrier organic
anion transporter family member 1B1] and
HMOX1 [heme oxygenase (decycling) 1]), were
associated at the nominal P-value. In the
exposomic analysis, we found an interaction
between adherence to MedDiet and the
genotype at the GWAS level. The SNP involved
was in the IL17B gene (P=3.14x10-8). Table 3
shows the gene*diet interaction results (top-
ranked SNPs).
Table 4: GWAS results for the interaction between smoking and the corresponding SNP
for bilirubin concentrations (top-ranked interactions)
DNA was isolated from blood. Genome-wide
genotyping was carried out using the Infinium
OmniExpress genotyping array and both
genome-wide association analyses (GWAS) and
candidate gene analyses were undertaken.
Epigenome-wide methylation analysis (EWAS)
was carried out using the Infinium
MethylationEPIC array (in a subsample). Serum
total bilirubin levels were measured by a
colorimetric method using the timed-endpoint
diazo method with 2,5-dichlorophenyl
diazonium. Adherence to the Mediterranean
diet (MedDiet), smoking and physical activity
were analyzed as environmental factors.
Statistical analysis, including adjustment for
covariates were carried out with PLINK, Partek
Genomics Suite and R.
Table 1. Demographic, clinical, lifestyle and genetic characteristics of the study participants at
baseline according to sex.
Total (n=430) Men (n=188) Women (n=242) P
Age (years) 65.1±0.2 63.9±0.4 66.1±0.3 <0.001
Weight (Kg) 84.5±0.7 92.8±1.0 78.0±0.6 <0.001
BMI (Kg/m2) 32.4±0.2 32.3±0.2 32.5±0.2 0.629
Waist circumference (cm) 106.1±0.5 111.2±0.6 102.0±0.6 <0.001
SBP (mm Hg) 141.6±0.9 143.8±1.3 139.9±1.2 0.026
DBP (mm Hg) 81.0±0.5 82.6±0.7 79.7±0.6 0.002
Total cholesterol (mg/dL) 196.4±1.8 188.3±2.8 202.6±2.3 <0.001
LDL-C (mg/dL) 125.0±1.5 121.6±2.4 127.7±1.9 0.044
HDL-C (mg/dL) 51.5±0.5 47.5±0.8 54.7±0.7 <0.001
Triglycerides (mg/dL) 141.6±2.9 138.2±3.8 144.3±4.2 0.296
Fasting glucose (mg/dL) 112.5±1.3 112.8±2.0 112.3±1.7 0.862
Bilirubin (mg/dL) 0.58±0.01 0.64±0.02 0.53±0.01 <0.001
AST (U/L) 26.4±0.4 27.7±0.7 25.4±0.5 0.005
ALT (U/L) 28.4±0.8 30.8±1.2 26.6±1.0 0.008
Type 2 diabetes: n, % 169 (39.3) 74 (39.4) 95 (39.3) 0.982
Current smokers: n, % 49 (11.4) 30 (16.0) 19 (7.9) <0.001
Medications: n, %
Antihypertensive drugs 339 (78.8) 148 (78.7) 191 (78.9) 0.959
Hypolipidemic drugs 278 (64.7) 125 (66.5) 153 (63.2) 0.482
Insulin 22 (5.1) 11 (5.9) 11 (4.5) 0.542
Physical Activity
(MET.min/wk) 1715±77 1940±134 1539±89 0.227
Adherence to MedDiet (P17)1 7.97±0.13 7.79±0.20 8.12±0.18 0.010
Values are mean±SE for continuous variables and number (%) for categorical variables.  BMI indicates
body mass index; MedDiet, Mediterranean diet; P: P-value for the comparisons (means or %) between
male and female individuals; AST: Aspartate transaminase;  ALT: Alanine transaminase; MET: Metabolic
Equivalent. 1 MET is equivalent to kcal·kg−1·h−1,  the oxygen cost of sitting quietly measured as 3.5
ml/kg/min; 1: Quantitative 17-item questionnaire for Adherence to Mediterranean diet (MedDiet).
Total serum bilirubin concentrations were
higher in men than in women, but in both
groups, the mean value of bilirubin
concentrations was within the normal limit (<=1
mg/dL generally proposed as reference).
Figure 3 shows adjusted means for total serum
bilirubin concentrations in men and women
after adjustment for age, diabetes, BMI,
medications, smoking, physical activity and
adherence to the MedDiet.
Table 2. GWAS results (the top-ranked SNPs) for the association between bilirubin
concentrations in the whole sample.
CHR SNP BETA SE R2 P1 P2 MA MAF Gene
2 rs4148325 0.149 0.016 0.174 1.97E-19 9.25E-24 C 0.354 UGT1A1
2 rs6742078 0.148 0.016 0.173 2.84E-19 1.29E-23 T 0.348 UGT1A1
2 rs887829 0.148 0.016 0.171 3.72E-19 1.39E-23 T 0.354 UGT1A1
2 rs4148324 0.147 0.016 0.170 4.62E-19 9.48E-24 G 0.353 UGT1A1
2 rs17863787 0.142 0.016 0.157 1.40E-17 4.70E-20 G 0.263 UGT1A64
2 rs17862875 0.146 0.017 0.152 4.46E-17 1.68E-20 A 0.295 UGT1A6
2 rs3771341 0.143 0.017 0.150 8.64E-17 2.65E-20 A 0.330 UGT1A1
2 rs6744284 0.141 0.017 0.144 4.39E-16 4.06E-18 T 0.390 UGT1A6
2 rs929596 0.136 0.017 0.132 8.14E-15 1.83E-18 G 0.324 UGT1A1
2 rs2070959 0.127 0.016 0.127 2.47E-14 3.78E-16 G 0.278 UGT1A6
2 rs1105879 0.121 0.016 0.123 8.14E-14 1.84E-15 C 0.325 UGT1A6
2 rs1105880 0.120 0.016 0.120 1.55E-13 3.30E-15 G 0.343 UGT1A6
2 rs2741045 0.119 0.017 0.109 2.50E-12 2.03E-14 T 0.159 UGT1A10
2 rs7583278 0.111 0.016 0.105 7.21E-12 3.87E-13 T 0.391 UGT1A6
2 rs2018985 0.111 0.016 0.103 1.19E-11 3.49E-14 G 0.441 UGT1A6
2 rs6725478 0.110 0.016 0.102 1.22E-11 5.42E-13 T 0.388 UGT1A6
2 rs7604115 0.106 0.016 0.088 3.28E-10 3.09E-12 T 0.350 UGT1A6
2 rs3755319 0.102 0.016 0.086 7.53E-10 7.28E-12 A 0.450 UGT1A1
2 rs4148326 0.101 0.016 0.085 8.03E-10 8.20E-12 T 0.480 UGT1A1
2 rs4663965 0.101 0.016 0.084 1.00E-09 1.10E-11 T 0.415 UGT1A6
2 rs4124874 0.100 0.016 0.083 1.04E-09 9.01E-12 T 0.412 UGT1A63
2 rs2008595 0.101 0.016 0.083 1.08E-09 1.67E-11 C 0.412 UGT1A6
2 rs1875263 0.102 0.016 0.084 1.10E-09 1.02E-10 T 0.417 UGT1A63
2 rs6431628 0.100 0.016 0.083 1.29E-09 1.30E-11 A 0.410 UGT1A6
2 rs2741027 0.102 0.016 0.083 1.32E-09 9.63E-12 A 0.177 __
2 rs10179091 0.100 0.016 0.083 1.34E-09 1.01E-11 T 0.482 UGT1A6
2 rs4663333 0.100 0.016 0.083 1.35E-09 1.38E-11 G 0.411 UGT1A6
2 rs4663963 0.100 0.016 0.083 1.35E-09 1.35E-11 T 0.420 UGT1A6
2 rs871514 0.100 0.016 0.082 1.37E-09 1.82E-11 T 0.428 UGT1A6
2 rs10197460 0.099 0.016 0.083 1.42E-09 2.32E-10 T 0.298 UGT1A10
2 rs2741029 0.102 0.017 0.081 1.79E-09 1.07E-11 G 0.177 UGT1A8
2 rs4399719 0.099 0.016 0.081 1.89E-09 1.63E-11 T 0.415 UGT1A6
2 rs2602373 0.102 0.017 0.080 2.16E-09 1.51E-11 C 0.177 UGT1A10
2 rs2602374 0.105 0.017 0.080 2.16E-09 2.36E-11 T 0.173 UGT1A10
2 rs4294999 0.098 0.016 0.079 3.15E-09 4.78E-11 A 0.426 UGT1A6
18 rs658995 0.286 0.047 0.079 3.33E-09 2.50E-08 A 0.282 CBLN2
2 rs10179094 0.096 0.016 0.078 3.75E-09 5.34E-10 A 0.297 UGT1A103
2 rs2741012 0.098 0.016 0.078 4.11E-09 3.22E-11 T 0.191 __
2 rs6724485 0.095 0.016 0.077 4.50E-09 1.12E-09 A 0.358 UGT1A10
2 rs12988520 -0.098 0.016 0.077 5.01E-09 6.94E-10 C 0.470 UGT1A6
2 rs13015720 0.096 0.016 0.077 5.06E-09 9.86E-10 A 0.362 UGT1A6
2 rs7572563 -0.098 0.016 0.077 5.43E-09 1.03E-09 G 0.403 UGT1A6
2 rs4261716 0.095 0.016 0.076 6.40E-09 1.45E-09 T 0.358 UGT1A10
2 rs17862866 -0.097 0.016 0.076 6.86E-09 1.12E-09 A 0.402 UGT1A6
2 rs6736743 0.094 0.016 0.075 7.24E-09 1.69E-09 A 0.362 UGT1A10
2 rs6736508 0.094 0.016 0.075 7.25E-09 1.68E-09 A 0.362 UGT1A10
2 rs12623271 0.094 0.016 0.075 7.65E-09 1.75E-09 G 0.362 UGT1A6
2 rs10168155 0.094 0.016 0.075 7.87E-09 1.69E-09 T 0.362 UGT1A10
2 rs6753320 0.093 0.016 0.074 1.03E-08 2.30E-09 C 0.363 UGT1A10
2 rs7563561 0.093 0.016 0.074 1.03E-08 2.30E-09 G 0.362 UGT1A10
2 rs4553819 0.093 0.016 0.074 1.05E-08 2.43E-09 G 0.358 UGT1A10
2 rs6753569 0.093 0.016 0.074 1.09E-08 2.39E-09 C 0.362 UGT1A10
2 rs4347832 0.093 0.016 0.074 1.13E-08 2.52E-09 C 0.358 UGT1A10
2 rs11680450 0.092 0.016 0.072 1.73E-08 3.54E-09 C 0.362 UGT1A10
2 rs7556676 0.093 0.017 0.069 3.51E-08 6.99E-10 G 0.497 UGT1A6
2 rs2361502 0.096 0.017 0.069 3.69E-08 1.17E-08 C 0.282 MROH2A
2 rs11690786 0.096 0.017 0.067 6.38E-08 7.05E-09 T 0.281 MROH2A
18 rs595333 0.252 0.046 0.066 7.46E-08 5.81E-07 T 0.291 CBLN2
3 rs6439106 0.409 0.077 0.062 1.79E-07 3.14E-08 T 0.221 __
Table 3.  GWAS results for the interaction term between Mediterranean diet adherence and the







CHR SNP BETA1 SE1 BETA2 SE2
P3 gene-diet
interaction MA MAF GENE
5 rs6887452 0.045 0.016 -0.087 0.018 3.14E-08 G 0.397 IL17B
10 rs6585514 -0.061 0.016 0.063 0.019 5.89E-07 A 0.395 __
6 rs7770270 -0.046 0.024 0.140 0.030 1.52E-06 A 0.112 LAMA2
17 rs1242492 0.038 0.015 -0.074 0.018 2.78E-06 C 0.249 __
4 rs13108021 0.052 0.017 -0.069 0.020 2.96E-06 A 0.228 __
10 rs10886342 0.059 0.017 -0.067 0.022 4.19E-06 A 0.277 __
18 rs12964365 -0.048 0.017 0.073 0.020 4.59E-06 T 0.150 LOC107985179
6 rs6904763 -0.046 0.024 0.128 0.030 5.32E-06 C 0.126 LAMA2
5 rs907195 0.054 0.017 -0.070 0.021 5.91E-06 C 0.253 __
4 rs10305895 0.061 0.020 -0.076 0.023 6.04E-06 G 0.341 EDNRA
1 rs11208512 0.037 0.016 -0.075 0.019 6.35E-06 T 0.417 __
5 rs7443165 -0.046 0.019 0.089 0.024 8.62E-06 A 0.277 __
10 rs4642993 -0.060 0.015 0.043 0.018 9.19E-06 A 0.455 __
18 rs687862 -0.043 0.017 0.074 0.020 9.70E-06 A 0.220 LINC01541
5 rs16871933 0.111 0.027 -0.072 0.031 9.70E-06 G 0.081 LINC01331
Chr SNP Position N Beta1 SE1 N2 Beta2 SE2 P_GXE Gene name
17 rs17688326 62109123 379 -0.024 0.018 49 0.2015 0.035 8.21E-09 intergenic
7 rs12540583 102760511 380 -0.0384 0.033 49 0.3405 0.067 4.15E-07 NAPEPLD
19 rs10409409 58215467 381 -0.0525 0.022 49 0.2149 0.048 4.46E-07 ZNF154
20 rs12106004 13562040 380 -0.0582 0.045 49 0.4879 0.099 5.21E-07 TASP1
21 rs9978194 35254293 380 -0.0424 0.027 48 0.2814 0.059 6.88E-07 ITSN1
Current smokersNon-smokers
We also analyzed the interaction between
smoking and the genome on serum  bilirubin at
the GWAS level. We obtained an interaction
with the rs17688326 (intergenic in chromoso-
me 17 at P = 8.21E-9). The following top-ranked
SPNs were located at NAPEPLD, ZNF154, TASP1,
ITSN1 genes (Table 4).
